
Watchmaker Genomics applies advanced enzymology to develop high-performance solutions for next-generation sequencing (NGS) to molecular diagnostics (MDx). By combining protein engineering innovation with scalable enzyme manufacturing, the company delivers the quality, consistency, and performance required for demanding clinical omics applications.
Founded in 2019 in Boulder, CO by Trey Foskett, Brian Kudlow, and Stephen Picone, Watchmaker brings together an experienced team with strong backgrounds in sequencing, enzyme engineering, and assay development. The founders have worked together for over a decade, with multiple successful exits totaling more than $2B.
Watchmaker’s integrated capabilities in computational biology, protein engineering, and manufacturing enable rapid, iterative design of precision enzymes and workflows to help bridge the gap between sample input and actionable data output.
At the intersection of biology, engineering, and computer science, Watchmaker is focused on enabling more accurate and reliable omics insights in clinical, translational, and emerging applications. The company’s mission is to ensure that sequencing data faithfully reflects the underlying biology, advancing both scientific discovery and human health.